AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18218291 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox dispersed in apple juice
Number of subjects: 28
Study 18218291 — intervention group
Group type: COMPARATOR
Intervention: Deferasirox dispersed in water (reference)
Number of subjects: 28
Study 16650240 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 96
Study 12867108 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1701
Study 12867108 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 1701
Study 12867108 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 1701
Study 10214099 — intervention group
Group type: EXPERIMENTAL
Intervention: Full capitation reimbursement incentive
Number of subjects: 710
Study 10214099 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-service reimbursement incentive
Number of subjects: 710
Study 10214099 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilization review scenarios
Number of subjects: 710
Study 10214099 — intervention group
Group type: COMPARATOR
Intervention: Insurance form completion scenarios
Number of subjects: 710
Study 7541916 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐6 (IL‐6) at doses of 0, 1, 2.5, or 5 micrograms/kg/d subcutaneously on days 4 to 13
Number of subjects: 15
Study 7541916 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony‐stimulating factor (G‐CSF) at a dose of 5 micrograms/kg/d subcutaneously beginning on day 4 until a postnadir absolute neutrophil count of more than 10 x 10(9)/L
Number of subjects: 15
Study 7541916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 2,000 mg/m2 with mesna 1,600 mg/m2 intravenously on days 1, 2, and 3, carboplatin 350 mg/m2 intravenously on day 1 only, and etoposide 75 mg/m2 intravenously on days 1, 2, and 3
Number of subjects: 15
Study 2365468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 154
Study 2365468 — intervention group
Group type: COMPARATOR
Intervention: Aztreonam plus cefazolin
Number of subjects: 154
Study 27064 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term salt depletion and peroral furosemide
Number of subjects: 19
Study 27064 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of propranolol
Number of subjects: 19
Study 27064 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with propranolol
Number of subjects: 19
Study 27064 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in PRA on propranolol (bolus/long-term)
Number of subjects: 19
Study 31765632 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS (20 min, 2 mA)
Number of subjects: 16
Study 31765632 — intervention group
Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 16
Study 30223023 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20 single injection (6 mL)
Number of subjects: 357
Study 30223023 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 357
Study 28341759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg daily) in Cohort R (R1)
Number of subjects: 10
Study 28341759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg every 12 hours) in Cohort NR (NR1)
Number of subjects: 10
Study 28341759 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir (CYP3A4 inhibitor)
Number of subjects: 10
Study 26667367 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid (EPA) at 1,800 mg/day
Number of subjects: 95
Study 26667367 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 95
Study 23745525 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline (HS) plus 0.1% hyaluronic acid (HA)
Number of subjects: 40
Study 23745525 — intervention group
Group type: COMPARATOR
Intervention: 7% hypertonic saline (HS)
Number of subjects: 40
Study 22768976 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV positive patients
Number of subjects: 60
Study 22768976 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV negative patients
Number of subjects: 60
Study 19647862 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-IR SLIT tablets
Number of subjects: 89
Study 19647862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 17880902 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretive labels (positive/abnormal results)
Number of subjects: 1688
Study 17880902 — intervention group
Group type: COMPARATOR
Intervention: No interpretive labels (numeric results alone)
Number of subjects: 1688
Study 14712427 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 (alfacalcidol, 0.5 microg/d)
Number of subjects: 60
Study 14712427 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K2 (menatetrenone, 45 mg/d)
Number of subjects: 60
Study 14712427 — intervention group
Group type: COMPARATOR
Intervention: Vitamins D3 plus K2
Number of subjects: 60
Study 14712427 — intervention group
Group type: COMPARATOR
Intervention: Control (prednisolone alone)
Number of subjects: 60
Study 12466776 — intervention group
Group type: EXPERIMENTAL
Intervention: SpinT goniometer
Number of subjects: 23
Study 12466776 — intervention group
Group type: COMPARATOR
Intervention: CROM instrument
Number of subjects: 23
Study 9805724 — intervention group
Group type: EXPERIMENTAL
Intervention: New rationalised programme of antenatal care
Number of subjects: 0
Study 9805724 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care
Number of subjects: 0
Study 7645443 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactivating occupational therapy in addition to functional rehabilitation
Number of subjects: 44
Study 7645443 — intervention group
Group type: COMPARATOR
Intervention: Functional rehabilitation alone
Number of subjects: 44
Study 31425350 — intervention group
Group type: EXPERIMENTAL
Intervention: VGG19 model
Number of subjects: 62
Study 31425350 — intervention group
Group type: EXPERIMENTAL
Intervention: Best ensemble model
Number of subjects: 62
Study 31425350 — intervention group
Group type: COMPARATOR
Intervention: Non-RB group
Number of subjects: 62
Study 29090986 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy (NPT) following cesarean section
Number of subjects: 467
Study 29090986 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (no NPT)
Number of subjects: 467
Study 27626390 — intervention group
Group type: EXPERIMENTAL
Intervention: The Incredible Years School Age Program (12 weekly 2-hour sessions)
Number of subjects: 22
Study 27626390 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 22
Study 27626390 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants pre- and post-intervention
Number of subjects: 22
Study 25650109 — intervention group
Group type: EXPERIMENTAL
Intervention: Light It Up advertisement
Number of subjects: 397
Study 25650109 — intervention group
Group type: COMPARATOR
Intervention: Neutral comparison advertisement
Number of subjects: 397
Study 23643576 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 11
Study 23643576 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine
Number of subjects: 11
Study 23643576 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 11
Study 23643576 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 11
Study 23643576 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Number of subjects: 11
Study 20495141 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperpnoea (IH)
Number of subjects: 30
Study 20495141 — intervention group
Group type: COMPARATOR
Intervention: Conventional recovery (control)
Number of subjects: 30
Study 19374795 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban 0.02 mg kg(‐1) h(‐1)
Number of subjects: 10
Study 19374795 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban 0.04 mg kg(‐1) h(‐1)
Number of subjects: 10
Study 19374795 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban 0.06 mg kg(‐1) h(‐1)
Number of subjects: 10
Study 16688993 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM)
Number of subjects: 0
Study 15136383 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg daily for 21 days)
Number of subjects: 34
Study 15136383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11291825 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual tracking task using a hand-held stylus over a digitizing tablet
Number of subjects: 67
Study 9108186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric formulation of ciprofloxacin (125 mg per capsule)
Number of subjects: 0
Study 9108186 — intervention group
Group type: COMPARATOR
Intervention: 250 mg tablets of ciprofloxacin
Number of subjects: 0
Study 9108186 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary concentrations of ciprofloxacin
Number of subjects: 0
Study 9108186 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary concentrations as a surrogate measure
Number of subjects: 0
Study 8275921 — intervention group
Group type: EXPERIMENTAL
Intervention: Medifoxamine (daily dose of 194 mg at day 28)
Number of subjects: 98
Study 8275921 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (daily dose of 161 mg at day 28)
Number of subjects: 98
Study 8275921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Medifoxamine and Imipramine
Number of subjects: 98
Study 2873890 — intervention group
Group type: COMPARATOR
Intervention: ACVP (doxorubicin, cyclophosphamide, and prednisolone in combination with vincristine)
Number of subjects: 247
Study 2873890 — intervention group
Group type: COMPARATOR
Intervention: ACTP (doxorubicin, cyclophosphamide, and prednisolone in combination with teniposide)
Number of subjects: 247
Study 2873890 — intervention group
Group type: COMPARATOR
Intervention: ACTVP (doxorubicin, cyclophosphamide, and prednisolone in combination with both vincristine and teniposide)
Number of subjects: 247
Study 2873890 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTVP
Number of subjects: 247
Study 2873890 — intervention group
Group type: EXPERIMENTAL
Intervention: ACVP
Number of subjects: 247
Study 2873890 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTP
Number of subjects: 247
Study 29368152 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) followed by sentinel lymph node biopsy (SNB)
Number of subjects: 13396
Study 27287209 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care (SC)
Number of subjects: 156
Study 27287209 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 156
Study 24554737 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional sulcus-fixated multifocal IOL (group A)
Number of subjects: 54
Study 24554737 — intervention group
Group type: COMPARATOR
Intervention: Conventional multifocal IOL (group B)
Number of subjects: 54
Study 24554737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 22377563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg daily for 28 days followed by 14 days off (arm 1)
Number of subjects: 73
Study 22377563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg daily continuously (arm 2)
Number of subjects: 73
Study 19324344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily)
Number of subjects: 60
Study 19324344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18714110 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (pharmacist case manager providing admission medication verification, medication teaching, discharge counseling, faxing discharge care plan, follow-up phone call)
Number of subjects: 1000
Study 18714110 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention (pharmacist case manager providing some level of communication)
Number of subjects: 1000
Study 18714110 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 1000
Study 16555577 — intervention group
Group type: EXPERIMENTAL
Intervention: Efonidipine (T‐ and L‐type Ca2+ channel blocker)
Number of subjects: 40
Study 16555577 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (L‐type Ca2+ channel blocker)
Number of subjects: 40
Study 16555577 — intervention group
Group type: EXPERIMENTAL
Intervention: Efonidipine
Number of subjects: 40
Study 16555577 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 40
Study 16555577 — intervention group
Group type: EXPERIMENTAL
Intervention: Efonidipine and Nifedipine
Number of subjects: 40
Study 16555577 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (20 individuals)
Number of subjects: 40
Study 12472980 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ibuprofen gel (Ibugel) 5% applied for at least 7 days
Number of subjects: 100
Study 12472980 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen 400 mg tablets (1200 mg daily) taken for at least 7 days
Number of subjects: 100
Study 12472980 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ibuprofen gel (Ibugel) 5%
Number of subjects: 100
Study 12472980 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen 400 mg tablets (1200 mg daily)
Number of subjects: 100
Study 10528960 — intervention group
Group type: EXPERIMENTAL
Intervention: AM (herbal remedy)
Number of subjects: 88
Study 8746878 — intervention group
Group type: EXPERIMENTAL
Intervention: Menorest 50
Number of subjects: 205
Study 8746878 — intervention group
Group type: COMPARATOR
Intervention: Estraderm TTS 50
Number of subjects: 205
Study 1778334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lederle-Takeda APDT vaccine
Number of subjects: 0
Study 1778334 — intervention group
Group type: COMPARATOR
Intervention: Lederle DTP vaccine
Number of subjects: 0
Study 1778334 — intervention group
Group type: EXPERIMENTAL
Intervention: Takeda APDT vaccine
Number of subjects: 0
Study 6168837 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline (100 mg twice daily)
Number of subjects: 15
Study 6168837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31977740 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless oral patient-controlled analgesia device for the delivery of oxycodone
Number of subjects: 30
Study 31977740 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving PRN oxycodone from nursing staff
Number of subjects: 30
Study 31088856 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted higher circulating alanine aminotransferase (ALT)
Number of subjects: 671106
Study 31088856 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted higher circulating aspartate aminotransferase (AST)
Number of subjects: 671106
Study 31088856 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted alkaline phosphatase (ALP)
Number of subjects: 671106
Study 31088856 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted γ‐glutamyl transferase (GGT)
Number of subjects: 671106
Study 31088856 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to higher fasting insulin
Number of subjects: 671106
Study 29075570 — intervention group
Group type: EXPERIMENTAL
Intervention: Transactional model education program (6 sessions over 2 months)
Number of subjects: 80
Study 29075570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 25442646 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical postoperative knee brace with adjustable range of motion (ROM) at 0° to 30°
Number of subjects: 64
Study 25442646 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical postoperative knee brace with adjustable range of motion (ROM) at 0° to 60°
Number of subjects: 64
Study 25442646 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical postoperative knee brace with adjustable range of motion (ROM) at 0° to 90°
Number of subjects: 64
Study 25442646 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical postoperative knee brace with adjustable range of motion (ROM) at 20° to 90°
Number of subjects: 64
Study 25442646 — intervention group
Group type: COMPARATOR
Intervention: Control group (without a knee brace)
Number of subjects: 64
Study 25442646 — intervention group
Group type: EXPERIMENTAL
Intervention: Other knee braces (patellofemoral realignment brace, ligament brace, valgus/osteoarthritis brace, elastic knee bandage)
Number of subjects: 64
Study 24134898 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient pain assessment using a 100‐mm visual analogue scale (VAS)
Number of subjects: 0
Study 24134898 — intervention group
Group type: COMPARATOR
Intervention: Provider pain assessment using a 100‐mm visual analogue scale (VAS)
Number of subjects: 0
Study 24134898 — intervention group
Group type: COMPARATOR
Intervention: Agreement on most painful time point of procedure
Number of subjects: 0
Study 23040791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-foot block (foot infiltration)
Number of subjects: 40
Study 23040791 — intervention group
Group type: COMPARATOR
Intervention: Sciatic nerve block (30mL of 7.5% ropivacaine)
Number of subjects: 40
Study 23040791 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Mid-foot block and Sciatic nerve block)
Number of subjects: 40
Study 19576082 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy scheme executed at day 1 and day 8 for 6 ‐ 8 cycles
Number of subjects: 62
Study 19576082 — intervention group
Group type: COMPARATOR
Intervention: ABVD chemotherapy scheme executed at day 1 and day 15 for 6 ‐ 8 cycles
Number of subjects: 62
Study 19576082 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 17381927 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly vitamin A supplementation
Number of subjects: 60
Study 15041582 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg)
Number of subjects: 60
Study 15041582 — intervention group
Group type: COMPARATOR
Intervention: Control (Vitamin C, 500 mg)
Number of subjects: 60
Study 11697443 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (68 mg M-3-G)
Number of subjects: 6
Study 11697443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine (58 mg M-3-G)
Number of subjects: 6
Study 11697443 — intervention group
Group type: EXPERIMENTAL
Intervention: Red grape juice (117 mg M-3-G)
Number of subjects: 6
Study 11697443 — intervention group
Group type: COMPARATOR
Intervention: Red wine and dealcoholized red wine
Number of subjects: 6
Study 11697443 — intervention group
Group type: EXPERIMENTAL
Intervention: Red grape juice
Number of subjects: 6
Study 9129483 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular milk (240 mL)
Number of subjects: 42
Study 9129483 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-hydrolyzed milk (240 mL)
Number of subjects: 42
Study 8199724 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (extended release) 5-20 mg
Number of subjects: 20
Study 8199724 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5-20 mg
Number of subjects: 20
Study 8199724 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of felodipine and enalapril
Number of subjects: 20
Study 8199724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8199724 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 20
Study 2901289 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 66
Study 31971474 — intervention group
Group type: EXPERIMENTAL
Intervention: Local heat therapy (HT) applied to one thigh (garment perfused with water at 52°C) for 8 consecutive weeks (90 min, 5 days/wk)
Number of subjects: 12
Study 31971474 — intervention group
Group type: COMPARATOR
Intervention: Control thigh (no treatment)
Number of subjects: 12
Study 31971474 — intervention group
Group type: EXPERIMENTAL
Intervention: Local heat therapy (HT)
Number of subjects: 12
Study 31157554 — intervention group
Group type: EXPERIMENTAL
Intervention: BUT 6 (BUT) strain
Number of subjects: 1680
Study 31157554 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Converter (HYB) strain
Number of subjects: 1680
Study 31157554 — intervention group
Group type: EXPERIMENTAL
Intervention: HYB birds of both sexes
Number of subjects: 1680
Study 31157554 — intervention group
Group type: EXPERIMENTAL
Intervention: Body lipid (g/100g bodyweight)
Number of subjects: 1680
Study 31157554 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall growth description
Number of subjects: 1680
Study 28453299 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-EP2006
Number of subjects: 174
Study 28453299 — intervention group
Group type: COMPARATOR
Intervention: Reference pegfilgrastim
Number of subjects: 174
Study 25476120 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use assessments
Number of subjects: 0
Study 24070632 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine-75% alcohol solution for cutaneous antisepsis
Number of subjects: 834
Study 21848781 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hour disaster training course
Number of subjects: 91
Study 21848781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 91
Study 20066924 — intervention group
Group type: EXPERIMENTAL
Intervention: Simon task on color
Number of subjects: 0
Study 20066924 — intervention group
Group type: EXPERIMENTAL
Intervention: Simon task on shape
Number of subjects: 0
Study 20066924 — intervention group
Group type: EXPERIMENTAL
Intervention: Simon task on orientation
Number of subjects: 0
Study 20066924 — intervention group
Group type: COMPARATOR
Intervention: Simon task on color or shape
Number of subjects: 0
Study 17215272 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention strategies
Number of subjects: 0
Study 17215272 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised trials
Number of subjects: 0
Study 17215272 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational epidemiology
Number of subjects: 0
Study 15522126 — intervention group
Group type: EXPERIMENTAL
Intervention: Toast with butter (17.5 g fat)
Number of subjects: 8
Study 15522126 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal with full-fat milk (17.5 g fat)
Number of subjects: 8
Study 15522126 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal with semi-skimmed milk (2.7 g fat)
Number of subjects: 8